Aktienanalyse zu Pacific Biosciences of California Inc (PACB)PACBPacific Biosciences of California Inc

Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Given the current price of $2.11, the recent revenue guidance cut to $155-$165 million from $165-$175 million raises concerns about future performance. The RSI of 54.49 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. However, with a forward P/E of 0 and a significant decline in revenue, caution is warranted. The main risk is the company's declining revenue trend, with a 10.6% decline over the past two years, which could impact future profitability.

6 analysts cover PACB: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 2.40.